Alopecia Areata: When Your Immune System Causes Hair Loss

What Is Alopecia Areata?

Alopecia areata (AA) is a condition where your immune system — which normally fights infections — mistakenly targets hair follicles. This causes hair to fall out in smooth, round patches, usually about the size of a coin. The follicles themselves are not permanently damaged; they're put into a dormant state by the immune attack, which is why regrowth is always possible once the inflammation is controlled.

AA affects men and women equally, with peak onset between ages 25-36, though it can start at any age — including childhood. About 2% of people will experience it at some point in their lifetime.

For most people, AA starts as one or a few small patches on the scalp. In some cases, it progresses to cover the entire scalp (alopecia totalis) or the entire body including eyebrows, eyelashes, and body hair (alopecia universalis).

What Causes It?

Alopecia areata is an autoimmune condition — your immune cells (specifically T-cells) attack hair follicles as if they were foreign invaders. The exact trigger is not fully understood, but several factors contribute:

Genetics: If a first-degree relative has AA, your risk is about 10 times higher than the general population. Multiple genes involved in immune regulation have been linked to the condition.

Other autoimmune conditions: People with AA are more likely to also have thyroid disease, vitiligo, type 1 diabetes, or other autoimmune conditions. About 16% of AA patients have a thyroid disorder.

Stress and triggers: While stress doesn't cause AA, significant physical or emotional stress may trigger a flare in someone who is genetically predisposed. Infections and hormonal changes have also been reported as triggers in some cases.

What Does It Look Like?

The hallmark is one or more round, smooth bald patches on the scalp — the skin itself looks normal, not scarred or inflamed. Other signs your dermatologist may look for include:

"Exclamation point" hairs: Short, broken hairs around the edges of a patch that are narrower at the base — a telltale sign of active AA.

Nail changes: Small pits or dents in the fingernails occur in about 10-20% of people with AA. Nail ridging or brittleness may also appear.

Sudden onset: Patches often appear over days to weeks, sometimes noticed first by a hairstylist. The patches are not itchy or painful in most cases, though some people report a tingling sensation before hair falls out.

Treatment Options

For limited patches (less than 50% of scalp):

Corticosteroid injections: Your dermatologist injects a small amount of steroid (triamcinolone) directly into each patch. This is the most common first-line treatment for small patches. Sessions are repeated every 4-6 weeks. Regrowth typically begins within 4-8 weeks of the first treatment. The injections cause brief discomfort but are well-tolerated.

Topical corticosteroids: Prescription-strength steroid creams or ointments applied to patches daily. Less effective than injections for scalp AA but useful for children or those who prefer a non-injection option.

Topical immunotherapy: A chemical (DPCP or squaric acid) is applied to the scalp to deliberately cause a mild allergic reaction. This "distracts" the immune system from attacking follicles. Weekly office visits are needed, and it takes 3-6 months for results. About 30-40% of patients with extensive AA respond.

For extensive hair loss (more than 50% of scalp):

JAK inhibitors (the breakthrough): These oral medications have transformed AA treatment. They block specific immune signaling pathways (JAK/STAT) that drive the follicle attack. FDA-approved options include:

Baricitinib (Olumiant): Approved for adults with severe AA. In clinical trials (BRAVE-AA1 and BRAVE-AA2), about 35-40% of patients achieved 80% or more scalp hair coverage after 36 weeks. Side effects can include upper respiratory infections, headaches, elevated cholesterol, and rare blood clot risk.

Ritlecitinib (Litfulo): Approved for adults and adolescents (12+). Clinical trials showed about 23% achieved 80% or more coverage at 24 weeks, with continued improvement over time. Side effects are generally mild.

These medications represent a genuine paradigm shift — before 2022, there were no FDA-approved treatments specifically for alopecia areata.

What to Expect

The course of AA is unpredictable. About 50% of people with limited patches regrow hair within a year without treatment. However, recurrence is common — about 85% of people experience more than one episode.

Factors associated with a more challenging course include: onset before puberty, extensive hair loss at first presentation, loss lasting more than a year, nail involvement, and having other autoimmune conditions. The more extensive the loss, the lower the chance of spontaneous regrowth — which is why the new JAK inhibitor treatments are so important for people with severe cases.

Frequently Asked Questions

Is alopecia areata contagious?

No — it is absolutely not contagious. You cannot catch it from someone or give it to anyone else. It is an autoimmune condition, meaning your own immune system is the cause.

Will my hair grow back the same color and texture?

When hair first regrows in an AA patch, it often comes in white or lighter than your natural color. This is normal. Over subsequent growth cycles, the color usually returns to its original shade. Some people notice slightly different texture initially, but this also typically normalizes over time.

Should my children be screened?

There's no routine screening test for AA. While having a parent with the condition does increase risk, most children of AA patients will never develop it. The best approach is simply to be aware — if you notice smooth bald patches on your child, see a dermatologist promptly.

Are JAK inhibitors safe long-term?

JAK inhibitors are relatively new for AA, so long-term safety data is still being collected. They carry a boxed warning about potential risks including serious infections, blood clots, and cardiovascular events — primarily based on data from older patients with rheumatoid arthritis. Your dermatologist will weigh risks versus benefits for your specific situation and monitor you regularly while on treatment.

References